B Cell, Corona Virus Infection, COVID, RDT, SARS-CoV 2
Conditions
Brief summary
This concerns a single-center prospective interventional cohort study. Laboratory-confirmed COVID-19 patients will be asked to donate blood at at least two different timepoints. This will allow us to investigate T and B cell evolutions during the course of infection and recovery. The expected duration of the study is four months or the total duration of the SARS-CoV-2 circulation in Belgium (whichever is shortest).
Interventions
None listed
Sponsors
University Hospital, Antwerp
Institute of Tropical Medicine, Belgium
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* laboratory confirmed COVID-19 acute infection * be older than 18 years of age * be hospitalized at the UZA * willing and able to provide written informed consent by the participant or its legal representative (for instance in case of medical incapacitation)
Exclusion criteria
* younger than 18 years old * Ambulatory patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| provide proof-of-concept that (longitudinal) B cell repertoire mining allows identification of emerging virus specific B cell receptor variable regions. | 4 months |
Secondary
| Measure | Time frame |
|---|---|
| study evolutions in B and T cell repertoires to understand COVID-19 specific immune responses fundamentally. | every 7 days during hospitalization a bloodsample is taken |
| clinical and epidemiological description of UZA hospitalized COVID-19 patients | at hospitalization |
Countries
Belgium
Outcome results
None listed